Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target?

Pomrenze MB, Fetterly TL, Winder DG, Messing RO.

Alcohol Clin Exp Res. 2017 Dec;41(12):1986-1999. doi: 10.1111/acer.13507. Epub 2017 Oct 25. Review.

PMID:
28940382
2.

Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?

Kranzler HR, Smith RV, Schnoll R, Moustafa A, Greenstreet-Akman E.

Addiction. 2017 Dec;112(12):2086-2094. doi: 10.1111/add.13818. Epub 2017 Apr 21.

PMID:
28431457
3.

Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity.

Cservenka A, Yardley MM, Ray LA.

Am J Addict. 2017 Aug;26(5):516-525. doi: 10.1111/ajad.12463. Epub 2016 Nov 4. Review.

4.

The Role of Pharmacotherapy in the Treatment of Adolescent Substance Use Disorders.

Hammond CJ.

Child Adolesc Psychiatr Clin N Am. 2016 Oct;25(4):685-711. doi: 10.1016/j.chc.2016.05.004. Epub 2016 Aug 2. Review.

5.

Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development.

Litten RZ, Falk DE, Ryan ML, Fertig JB.

Alcohol Clin Exp Res. 2016 Jul;40(7):1368-79. doi: 10.1111/acer.13093. Epub 2016 May 17. Review.

6.

Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse.

Van Skike CE, Maggio SE, Reynolds AR, Casey EM, Bardo MT, Dwoskin LP, Prendergast MA, Nixon K.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:269-87. doi: 10.1016/j.pnpbp.2015.11.004. Epub 2015 Nov 12. Review.

7.

Variation in the Serotonin Transporter Gene and Alcoholism: Risk and Response to Pharmacotherapy.

Thompson MD, Kenna GA.

Alcohol Alcohol. 2016 Mar;51(2):164-71. doi: 10.1093/alcalc/agv090. Epub 2015 Aug 26. Review.

8.

Serotonergic gene variation in substance use pharmacotherapy: a systematic review.

Bauer IE, Graham DP, Soares JC, Nielsen DA.

Pharmacogenomics. 2015;16(11):1307-14. doi: 10.2217/pgs.15.72. Epub 2015 Aug 12. Review.

9.

Advances in Medications and Tailoring Treatment for Alcohol Use Disorder.

Seneviratne C, Johnson BA.

Alcohol Res. 2015;37(1):15-28. Review.

10.

Recommendations for the Design and Analysis of Treatment Trials for Alcohol Use Disorders.

Witkiewitz K, Finney JW, Harris AH, Kivlahan DR, Kranzler HR.

Alcohol Clin Exp Res. 2015 Sep;39(9):1557-70. doi: 10.1111/acer.12800. Epub 2015 Aug 6. Review.

11.

Alcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence.

García ML, Blasco-Algora S, Fernández-Rodríguez CM.

World J Gastroenterol. 2015 Jul 28;21(28):8516-26. doi: 10.3748/wjg.v21.i28.8516. Review.

12.

Subgroup Identification in Personalized Treatment of Alcohol Dependence.

Hou J, Seneviratne C, Su X, Taylor J, Johnson B, Wang XQ, Zhang H, Kranzler HR, Kang J, Liu L.

Alcohol Clin Exp Res. 2015 Jul;39(7):1253-9. doi: 10.1111/acer.12759. Epub 2015 May 29.

13.

The pharmacogenetics of alcohol use disorder.

Jones JD, Comer SD, Kranzler HR.

Alcohol Clin Exp Res. 2015 Mar;39(3):391-402. doi: 10.1111/acer.12643. Epub 2015 Feb 19. Review.

14.

The 5-HT7 receptor as a potential target for treating drug and alcohol abuse.

Hauser SR, Hedlund PB, Roberts AJ, Sari Y, Bell RL, Engleman EA.

Front Neurosci. 2015 Jan 13;8:448. doi: 10.3389/fnins.2014.00448. eCollection 2014. Review.

15.

Molecular basis of alcoholism.

Most D, Ferguson L, Harris RA.

Handb Clin Neurol. 2014;125:89-111. doi: 10.1016/B978-0-444-62619-6.00006-9. Review.

16.

Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings.

Kenna GA, Zywiak WH, Swift RM, McGeary JE, Clifford JS, Shoaff JR, Fricchione S, Brickley M, Beaucage K, Haass-Koffler CL, Leggio L.

Alcohol. 2014 Sep;48(6):515-22. doi: 10.1016/j.alcohol.2014.04.005. Epub 2014 Aug 14.

17.

Alcohol use disorder clinical course research: informing clinicians' treatment planning now and in the future.

Maisto SA, Kirouac M, Witkiewitz K.

J Stud Alcohol Drugs. 2014 Sep;75(5):799-807. Review.

18.

Serotonin Transporter Genotype Linked to Adolescent Substance Use Treatment Outcome through Externalizing Behavior.

Chung T, Cornelius JR, Martin CS, Ferrell R, Maisto SA, Clark DB.

Front Pediatr. 2014 Jul 7;2:71. doi: 10.3389/fped.2014.00071. eCollection 2014.

19.

5-HTTLPR moderates naltrexone and psychosocial treatment responses in heavy drinking men who have sex with men.

Chen AC, Davis CM, Kahler CW, Kuerbis AN, Covault J, Kranzler HR, Morgenstern J.

Alcohol Clin Exp Res. 2014 Sep;38(9):2362-8. doi: 10.1111/acer.12492. Epub 2014 Jul 28.

20.

The Genetics, Neurogenetics and Pharmacogenetics of Addiction.

Demers CH, Bogdan R, Agrawal A.

Curr Behav Neurosci Rep. 2014 Mar 1;1(1):33-44.

Supplemental Content

Support Center